Loading
Avelos Therapeutics is a Seoul company making targeted tablets that exploit weaknesses in how cancer cells divide and repair their DNA. Its first drug, AD1208, blocks a cell-division enzyme called MASTL and is in an early trial in advanced solid tumours.
Avelos Therapeutics Inc., based in Magok, Gangseo-gu, Seoul, was established on 1 September 2021, according to the company, and develops biomarker-driven small-molecule targeted therapies in DNA damage response, cell cycle checkpoints and synthetic lethality. Its lead programme AVS1001 (AD1208), a MASTL inhibitor licensed in December 2021 under a collaboration and licensing agreement with a UK research institute, entered a phase 1 trial in December 2024; four further DDR and synthetic lethality programmes (AVS1002 to AVS1005) are in discovery. The company records seed investment from Myriad Lifesciences and Infobank in 2022, a KRW 10 billion Series A in July 2022, a KRW 17 billion Series B in April 2024, and a strategic investment and joint development agreement with Hyundai Pharm in March 2025. Its first registered cancer trial, NCT06911333, a phase 1/2a study of AD1208 alone or in combination in progressive, locally advanced or metastatic solid tumours at Korean sites, was posted on ClinicalTrials.gov in April 2025.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/